Suppr超能文献

体重指数-用力肺活量百分比-呼吸住院情况:特发性肺纤维化患者的新分期

Body mass index-percent forced vital capacity-respiratory hospitalization: new staging for idiopathic pulmonary fibrosis patients.

作者信息

Kishaba Tomoo, Nagano Hiroaki, Nei Yuichiro, Yamashiro Shin

机构信息

Department of Respiratory Medicine, Okinawa Chubu Hospital, Uruma City, Japan.

出版信息

J Thorac Dis. 2016 Dec;8(12):3596-3604. doi: 10.21037/jtd.2016.12.49.

Abstract

BACKGROUND

Idiopathic pulmonary fibrosis (IPF) is relentless progressive interstitial lung disease. Evaluating predictor of mortality for IPF patients is crucial. The aim of this study was to evaluate the serial trend of important indicators of prognosis and create a useful staging method for IPF patients.

METHODS

We retrospectively searched medical records, pulmonary function tests (PFTs), and chest high resolution computed tomography (HRCT) scans from January 1, 2008 through June 30, 2015 at our hospital. We also evaluated the same parameters 1-year later.

RESULTS

We identified 65 IPF patients. The mean age was 71.9±1.8 years (range, 22-85 years). In terms of PFTs, mean percent predicted forced vital capacity (%FVC) was 69.8±2.7. Baseline mean body mass index (BMI) was 24.3±0.6 kg/mm. Mean survival was 39.2 months (range, 0.9-158.9 months). Cox proportional hazard ratios (HRs) showed the following to be predictors of mortality in IPF patients: 1-year BMI (HR: 0.899; 95% CI: 0.825-0.979; P=0.021); 1-year %FVC (HR: 0.932; 95% CI: 0.887-0.979; P=0.005) and 1-year respiratory hospitalization (HR: 3.307; 95% CI: 2.149-5.090; P<0.001). On the basis of these date, we created a new staging method for predicting mortality for IPF patients, consisting of delta BMI, delta %FVC and respiratory hospitalization within a year following diagnosis of IPF (BFR staging). We stratified patients into one of three groups according to the composite points. Mean survival of stages 1, 2, and 3 was 77.9 (30.8-158.9), 43.9 (0.9-145.2) and 14.8 (3.5-32) months (P<0.001), respectively.

CONCLUSIONS

In our cohort of IPF patients, this new staging method, including delta BMI and delta %FVC and respiratory hospitalization within 1-year showed a clear survival difference.

摘要

背景

特发性肺纤维化(IPF)是一种持续进展的间质性肺病。评估IPF患者的死亡率预测指标至关重要。本研究旨在评估预后重要指标的系列变化趋势,并为IPF患者创建一种有用的分期方法。

方法

我们回顾性检索了我院2008年1月1日至2015年6月30日期间的病历、肺功能测试(PFT)和胸部高分辨率计算机断层扫描(HRCT)。我们还在1年后评估了相同参数。

结果

我们确定了65例IPF患者。平均年龄为71.9±1.8岁(范围22 - 85岁)。在肺功能测试方面,预测的用力肺活量平均百分比(%FVC)为69.8±2.7。基线平均体重指数(BMI)为24.3±0.6kg/mm²。平均生存期为39.2个月(范围0.9 - 158.9个月)。Cox比例风险比(HR)显示以下为IPF患者死亡率的预测指标:1年BMI(HR:0.899;95%CI:0.825 - 0.979;P = 0.021);1年%FVC(HR:0.932;95%CI:0.887 - 0.979;P = 0.005)和1年呼吸住院次数(HR:3.307;95%CI:2.149 - 5.090;P < 0.001)。基于这些数据,我们为预测IPF患者死亡率创建了一种新的分期方法,由IPF诊断后1年内的BMI变化、%FVC变化和呼吸住院次数组成(BFR分期)。我们根据综合得分将患者分为三组之一。1期、2期和3期的平均生存期分别为77.9(30.8 - 158.9)、43.9(0.9 - 145.2)和14.8(3.5 - 32)个月(P < 0.001)。

结论

在我们的IPF患者队列中,这种新的分期方法,包括BMI变化、%FVC变化和1年内呼吸住院次数,显示出明显的生存差异。

相似文献

引用本文的文献

本文引用的文献

10
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.尼达尼布治疗特发性肺纤维化的疗效和安全性。
N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验